세계 일회용 바이오프로세싱 시장 규모는 2023년 211억 1,000만 달러에서 2024-2031년의 예측 기간 동안 17.61%의 연평균 복합 성장률(CAGR)로 성장하여 2031년 772억 9,000만 달러 규모로 성장할 것으로 예상됩니다. 이 시장은 최근 몇 년동안 괄목할 만한 성장세를 보였으며, 앞으로도 강력한 성장세를 유지할 것으로 예상됩니다.
일회용 바이오 프로세서는 세척이나 재조립이 필요 없이 1회 사용 후 폐기할 수 있도록 설계되었습니다. 시간, 비용, 노동력 등 매우 중요한 요소를 모두 절약할 수 있어 제약 및 바이오 제약 산업 및 기타 산업에 유용하고 효율적입니다. 일회용 바이오프로세싱 시장은 기술 발전, 바이오프로세싱 공정에 대한 수요 증가, 제약 및 바이오 의약품에 대한 수요 증가, 이러한 설정의 비용 효율성 등의 요인으로 인해 성장하고 있습니다. 업계 대기업과 실무자들은 업계 전문가들에게 최고의 기술을 제공하기 위해 협력하고 있습니다. 공공 기관과 영리 단체 모두 양질의 솔루션을 제공하기 위해 자금을 조달하고 많은 투자를 하고 있습니다. 이들 대기업들은 신제품을 개발하거나 도입할 때 제휴, 투자, 인수합병(M&A) 등의 전략적 수단을 활용하고 있습니다.
단일 사용 바이오프로세서의 비용 효율성이 시장 성장을 가속하는 이유:
세계 일회용 바이오프로세서 시장의 성장을 가속하는 두 가지 주요 요인은 비용 효율성과 효율성입니다. 비용과 효율성 측면에서 일회용 바이오 프로세서는 여러 측면에서 기존 스테인리스 스틸 바이오 프로세서보다 우수합니다. 일회용 바이오 프로세서는 설비 투자가 적고, 이것이 주요 장점 중 하나입니다. 일회용 바이오 프로세서는 표준 바이오 프로세서보다 운영 비용이 낮기 때문에 중소기업과 R&D에 매력적인 선택이 될 수 있습니다. 백, 필터, 센서와 같은 일회용 부품은 고비용과 시간이 많이 소요되는 세척 및 멸균 작업의 필요성을 줄여줍니다. 따라서 배치 간 이차 오염 가능성이 낮아져 보다 안정적이고 일관된 결과를 보장합니다.
세계 일회용 바이오프로세싱(Single-Use Bioprocessing) 시장을 조사했으며, 시장 정의와 개요, 시장 규모 추이와 예측, 각종 부문별/지역별 상세 분석, 산업 구조, 시장 성장에 영향을 미치는 요인 분석, 사례 연구, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
Global single-use bioprocessing market is projected to witness a CAGR of 17.61% during the forecast period 2024-2031F, growing from USD 21.11 billion in 2023 to USD 77.29 billion in 2031F. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.
Single-use bioprocessors are designed to be disposed of after one use without the need to be cleaned or re-assembled. These are useful and efficient for pharmaceutical and biopharmaceutical industries and other such industries because they save time, money, and labor, all of which are very important. The single-use bioprocessing market is growing due to this reason mainly among a few other reasons such as technological advancements, rising needs for bioprocessing processes, rising need for pharmaceuticals and biopharmaceuticals, and cost-effectiveness of such setups. Giants in the industry and practitioners are collaborating to provide the best technology for industry professionals. Both public and commercial organizations are raising money and investing a sizable sum of it to be able to provide quality solutions. These massive corporations use strategic maneuvers like collaborations, investments, and mergers and acquisitions when they are striving to develop or introduce a new product. For instance, Cytiva introduced X-platform bioreactors in April 2023 in an effort to streamline upstream bioprocessing procedures for single-use.
Merck KGaA announced that it would introduce Ultimus Film in April 2023 to assist single-use bioprocessing by providing superior strength and leak resistance in single-use assemblies. It is one of the most renowned technologies present today.
Cost Effectiveness of Single-Use Bioprocessors to Propel Market Growth
Two major drivers propelling the growth of the global market for single-use bioprocessors are cost-effectiveness and efficiency. In terms of cost and efficiency, single-use bioprocessors are superior to conventional stainless-steel bioprocessors in several ways. Capital investment is lower in the case of single-use bioprocessors, which is one of its main benefits. Single-use bioprocessors require significantly less capital investment than traditional stainless-steel bioprocessors, which calls for larger upfront capital inputs in equipment and infrastructure. Since single-use bioprocessors have lower operating costs than standard bioprocessors, they are an appealing alternative for small and medium-sized businesses and research and development due to their lower capital expenses. Single-use parts like bags, filters, and sensors lessen the need for cleaning and sterilizing, which are expensive and time-consuming tasks. As a result, there is less chance of cross-contamination across batches, guaranteeing more reliable and consistent results. Single-use bioprocessors provide greater flexibility, resulting in higher efficiency. They enable quicker product turnaround times because they are simple and quick to set up. Single-use bioprocessors are perfect for small-scale manufacturing and research and development since they can adjust more easily to changes in process needs.
For instance, in October 2022, PharmNXT Biotech opened its first integrated production facility in Pune to deliver single-use bioprocessing solutions that are also cost-effective. The facility tackles the obstacles faced by India's biologics production industry with its launch.
Technological Advancements to Contribute to the Market Growth
Research and technological developments are two major factors propelling the growth of the global single-use bioprocessing market. The need for more effective and affordable bioprocessing technologies is rising as the biopharmaceutical industry develops and grows. New materials and manufacturing techniques have made it possible to produce more sophisticated single-use bioprocessors that possess improved performance, dependability, and scalability. For instance, researchers have developed single-use bioprocessors that are more robust and resistant to a greater variety of chemicals and temperature ranges using modern polymers like polyethylene and polypropylene. The need for single-use bioprocessors has been further fueled by improvements in process control and automation, which have made bioprocessing activities more accurate and productive. Automation technologies can help speed up and improve the precision of bioprocessing activities while lowering the danger of contamination and operator mistakes. Bioprocessors can now be monitored and controlled in greater detail due to the development of increasingly advanced sensors and analytical instruments. Higher product yields, lower costs, and increased process efficiency are the results of this. Higher-end single-use bioprocessors are projected to become more and more in demand as long as research on biopharmaceuticals uncover new uses. The global market for single-use bioprocessors will continue to grow and innovate because of these developments, offering more affordable and effective bioprocessing solutions to satisfy the demands of the biopharmaceutical sector. For instance, Sartorius AG announced the release of BIOSTAT STR 1000, a new single-use bioreactor system, in March 2022. The system includes cutting-edge automation and control features and was created to satisfy the increasing need for large-scale bioprocessing.
Increasing Demand for Biopharmaceuticals to Fuel Market Growth
Over the course of the forecast period, the single-use bioprocessing market is anticipated to see considerable growth in the biopharmaceutical category. It results from growing business operations, rising demand for biologics, and growing acceptance of single-use technologies and systems. Additionally, the biopharmaceutical industry is adopting single-use technologies and products more frequently due to their benefits, such as lower labor and material costs, easier disposal compared to conventional bioprocessing methods, and lower initial investment and R&D costs. These one-time bioprocessing units are also widely employed by manufacturers and yield a 35% better carbon dioxide balance than stainless steel reactors used in traditional bioprocessing. The need for single-use bioprocessors is also rising due to the growing number of biologics approvals. For example, the United States Food and Drug Administration (US FDA) authorized Bioverativ Therapeutics Inc.'s ALTUVIIIO, a first-in-class, high-sustained factor VIII replacement medication, in February 2023. It is recommended for adults and children with hemophilia A for perioperative management (surgery), on-demand treatment to control bleeding episodes, and routine prophylaxis. Additionally, the FDA also approved Moderna, Inc.'s biologics license application for SPIKEVAX (the COVID-19 vaccine, mRNA) in January 2022, the biotechnology company responsible for pioneering messenger RNA (mRNA) therapies and vaccines submitted the application to prevent COVID-19 in people 18 years of age and older.
Additionally, it is anticipated that the firms' increased emphasis on implementing crucial strategies including partnerships, introducing new products, and other activities will support the segment's growth. In addition, the companies are expanding their process development, protein, and cell line offerings by establishing single-use bioprocessing facilities. Thermo Fisher Scientific Inc., for example, established a 55,000 square foot single-use technology (SUT) plant in Ogden in April 2022. The goal is to produce more single-use bioprocess containers so that treatments and vaccines can be developed. The plant offers more capability for producing different methods and materials required for creating novel treatments and vaccinations. The plant produces bioprocess container (BPC) systems that may be customised to deliver, process, separate, store, and move liquids.
North America to Dominate the Single-Use Bioprocessing Market
Over the course of the projected period, North America is anticipated to hold a sizable market share. It is caused by rising R&D expenses, sizable manufacturing facilities in the region, the rising demand for disposable items and healthcare costs, and a robust healthcare infrastructure. The government is making significant investments in developing biopharmaceutical products, which is anticipated to fuel demand for media, filtration assemblies, containers, single-use bioprocessors, and other items, thereby expanding the market. Additionally, the region's market is expanding because of growing firm initiatives to build single-use bioprocessing facilities and provide new goods such as filter assemblies, bioprocessors, and other consumables. Liquid single-use bioprocessing bags, for example, were introduced by ILC Dover LP in May 2022 to handle and distribute sterile liquids to the biotherapeutics market. With the help of this launch, the business was able to set up the whole biotherapeutic and pharmaceutical manufacturing process, from handling and containing powder to handling sterile liquid and pre-filled powder and liquid bags.
Future Market Scenario (2024-2031F)
One of the main factors contributing to the anticipated growth of the global single-use bioprocessing market is the increasing demand for biopharmaceuticals. Not only that, but the rising population and cases of chronic diseases, such as cancer, are also factors that will always propel market growth in the future. Given that technology is advancing, we can expect cutting-edge technology in the area also. Players in this market are expanding at an unparalleled rate, introducing cost-effective and efficient technologies. For instance, new single-use bioprocess containers under the brand name IRIS have been added to the product portfolio of Austrian solution provider Single Use Support GmbH in August 2022. With IRIS single-use bags in robust storage and shipping (RoSS) Shell, this expansion helps the business store and distribute drug items more securely.
Key Players Landscape and Outlook
Several companies such as Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Sartorius AG, Repligen Corporation, Cytiva, Saint-Gobain, Avantor, Inc., Sentinel Process Systems, Inc., Corning Incorporated, etc., are expanding business by planning and adopting new strategies. They are complying with new strategic initiatives regarding the launches of newly developed single-use bioprocessors, to help researchers and to bring up their presence in the market. New product launches, agreements based on contracts, acquisitions and mergers, investments and partnerships are a few ways through which they are trying to achieve the same.
To promote innovation in upstream bioprocessing, Cytiva and Culture Biosciences partnered in June 2023 to give clients more access to reliable and predictive scale-up capabilities.
In August 2023, Sartorius AG and Repligen Corporation announced the launch of an integrated bioreactor system that streamlines the implementation of N perfusion and intensified seed train for biopharmaceutical manufacturers by integrating Repligen XCell ATF upstream intensification technology into Sartorius' Biostat STR(R) bioreactor.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.